ClinicalTrials.gg
CompletedNCT02283814Updated Apr 11, 2025Results posted

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

A Phase 1 interventional study of BIA 2-093 and Topamax in Epilepsy, sponsored by Bial - Portela C S.A.. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing eslicarbazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. eslicarbazepine · Epilepsy.

Enrollment
22nd of 45
32 · median 32
Started
2007
with 6 others
Phase 1
29 of 45
none open now
Registered
33rd of 45
by date
Lead sponsor
40 of 45
Bial - Portela C S.A.

Among the 45 studies testing eslicarbazepine in Epilepsy, this one is the 22nd largest by enrollment, is one of 7 that started in 2007, is one of 29 in phase 1, and was the 33rd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 45 studies testing eslicarbazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About eslicarbazepine

eslicarbazepine: first FDA approval 2013 (APTIOM), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing eslicarbazepine in Epilepsy as a file.
02

Study summary

Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers

Read the detailed description

Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of Topamax (TPM) in last phases; Group B: Pre-treatment with TPM, treatment with TPM and ascending doses of ESL in last phases

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the form (ICF) duly read, signed and dated by the volunteer
  • Male aged of at least 18 years but not older than 45 years with a body mass índex () greater than or equal to 19 and below 30 kg/m
  • Clinical laboratory values within the laboratory's stated normal range; i f not within this range, they must be without any clinical significance (laboratory tests are presented in section 6.1.1.3)
  • Healthy according to the medical history, laboratory results and physical
  • Light-, non- or ex-smokers. A light smoker is defined as someone smoking 1 0 cigarettes or less per day, and an ex-smoker i s defined as someone who completely stopped smoking for at least 1 2 months before day 1 of this study

Exclusion criteria

Exclusion Criteria:

  • Significant history of to topiramate, eslicarbazepine, oxcarbazepine, carbamazepine or any related products (including of the formulations) as wel l as severe hypersensitivity reactions (like angioedema) to any drugs
  • Presence of significant gastrointestinal, l iver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  • History of significant gastrointestinal, liver o r kidney disease, o r surgery that may affect drug bioavailability, including but not limited to cholecystectomy
  • Presence of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic d isease
  • Presence o f significant heart disease o r disorder according to
  • Presence or history of significant central nervous system disorder l ike convulsion or depression
  • Presence o r history o f significant ocular disease
  • Presence or history of severe hepatic impairment
  • Presence or history of renal insufficiency (serum creatinine level greater than 135 μmol/L)
  • History or presence of acidosis
  • Use of valproic acid in the previous 7 days prior to Day 1 of the study.
  • Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  • Any illness in the previous 28 days before day 1 of this study
  • Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, , phenytoin and rifampin), in the previous 28 days before Day 1 of this study
  • Participation in another clinical trial or donation of 50 mL or more of blood in the previous 28 days before day 1 of this study
  • Donation of 500 mL or more of blood (Canadian B lood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
  • Positive urine screening of drugs of abuse (drugs listing is presented in section 6.1.1.4).
  • Positive results to HIV, or anti- tests
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group A BIA 2-093 + Topamax

    Group A * Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days; * Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days * Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days * Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days * Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days

    Drug: BIA 2-093 · Drug: Topamax

  • Experimental
    Group B BIA 2-093 + Topamax

    * Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days; * Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days; * Treatment: 200 mg once daily dose of TPM administered for four consecutive days; * Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days * Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days

    Drug: BIA 2-093 · Drug: Topamax

Interventions

  • Also known as: ESL, Eslicarbazepine acetate

  • Also known as: TPM

06

What researchers measure

Primary outcomes

  1. Cmax - the Maximum Plasma Concentration

    BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate

    Time frame: Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h

  2. Tmax - the Time of Occurrence of Cmax

    BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate Both Groups A and B described in participant flow recieved BIA 2-093 and Topiramate. The results presented here are related with the different interventions in both groups

    Time frame: Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h

Secondary outcomes

  1. AUCτ - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.

    BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate

    Time frame: Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h

07

Results

Posted Dec 22, 2014

Participant flow

Participant flow — Overall Study
MilestoneGroup A BIA 2-093 + TopamaxGroup B BIA 2-093 + Topamax
Started1616
Completed1314
Not completed32

Outcome measures

PrimaryCmax - the Maximum Plasma Concentration

BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate

Time frame:
Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h
Reported as:
Mean · ng/mL
Cmax - the Maximum Plasma Concentration
ng/mLBIA 2-093 + TPMBIA 2-093
Cmax (BIA 2-194)21960.6 ± 248225414.8 ± 3736
Cmax (BIA 2-195)931.8 ± 2161062.6 ± 235
PrimaryTmax - the Time of Occurrence of Cmax

BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate Both Groups A and B described in participant flow recieved BIA 2-093 and Topiramate. The results presented here are related with the different interventions in both groups

Time frame:
Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h
Reported as:
Mean · hours
Tmax - the Time of Occurrence of Cmax
hoursBIA 2-093 + TPMBIA 2-093
Tmax (BIA 2-194)2.00 ± 0.962.00 ± 0.97
Tmax (BIA 2-195)9.00 ± 4.206.00 ± 3.91
SecondaryAUCτ - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.

BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate

Time frame:
Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h
Reported as:
Mean · ng*h/mL
AUCτ - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.
ng*h/mLBIA 2-093 + TPMBIA 2-093
AUCτ (BIA 2-194)361733.9 ± 38706389794.3 ± 35861
AUCτ (BIA 2-195)19611.8 ± 470722886.8 ± 5195

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A BIA 2-093 + Topamax—0/16 (0%)15/16 (93.8%)
Group B BIA 2-093 + Topamax—0/16 (0%)13/16 (81.3%)
Most frequent other events
Showing 10 of 82
Most frequent other events
EventGroup A BIA 2-093 + TopamaxGroup B BIA 2-093 + Topamax
SomnolenceNervous system disorders14/1613/16
Paraesthesia oralNervous system disorders8/163/16
Abdominal distensionGastrointestinal disorders1/167/16
HeadacheNervous system disorders7/164/16
Lip dryGastrointestinal disorders5/166/16
FatigueGeneral disorders5/166/16
DizzinessNervous system disorders5/161/16
ConstipationGastrointestinal disorders4/162/16
Disturbance in attentionNervous system disorders4/161/16
ParaesthesiaNervous system disorders1/164/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group A BIA 2-093 + TopamaxGroup B BIA 2-093 + TopamaxTotal
<=18 years000
Between 18 and 65 years131427
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Group A BIA 2-093 + TopamaxGroup B BIA 2-093 + TopamaxTotal
Female000
Male131427
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 5, 2014
Start
Jan 2007
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Dec 22, 2014
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02283814
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Jan 2007
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Dec 22, 2014
Last update
Apr 11, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eslicarbazepine

Start the discussion